[go: up one dir, main page]

SG11201903283UA - Methods and compositions for tusc2 immunotherapy - Google Patents

Methods and compositions for tusc2 immunotherapy

Info

Publication number
SG11201903283UA
SG11201903283UA SG11201903283UA SG11201903283UA SG11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA SG 11201903283U A SG11201903283U A SG 11201903283UA
Authority
SG
Singapore
Prior art keywords
international
pct
tusc2
therapy
english
Prior art date
Application number
SG11201903283UA
Inventor
Jack Roth
Lin Ji
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11201903283UA publication Critical patent/SG11201903283UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111010111 01111101011H011H11011111111111111011111111111111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2018/071668 Al 19 April 2018 (19.04.2018) W I PO I PCT (51) International Patent Classification: (74) Agent: MANN, Monica; Parker Highlander PLLC, 1120 S. A61K 38/17 (2006.01) A61K 48/00 (2006.01) Capital of Texas Highway, Building One, Suite 200, Auatin, A61K 39/395 (2006.01) C07K 14/47 (2006.01) TX 78746 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/056338 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 12 October 2017 (12.10.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/407,329 12 October 2016 (12.10.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: BOARD OF REGENTS, THE UNIVERSI- TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., (84) Designated States (unless otherwise indicated, for every Austin, TX 78701 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: ROTH, Jack, A.; 6516 Brompton Road, Hous-UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, ton, TX 77005 (US). JI, Lin; 2323 Cypress Run Dr., Sugar TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Land, TX 77478 (US). — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Title: METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY = (54) = Supplement 4 PD1 vs Combination _ = -value Fold change _ p Cd7d2 0.006 7.21 = Lit 0.017 361 = \"0- H60a 0.046 264 -I.. 001 0.018 2.53 j = Q Infsf18 0.049 2.5 = Bd6 0.044 1 .5 = = _ 1112rb2 0.026 -6.18 = — Cd59b 0.05 3.94 N5 = '3' Cdl 0.025 -3.5 Merl 0.024 -2.5 Klra5 0.031 -2.2 Egr3 0.016 -2.18 1-1 Cd46 0.027 -1.6 GO ,-1 FIG, 10 IN © -.... ,-1(57 00 ) : A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 0 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided. ei o [Continued on next page] WO 2018/071668 Al MIDEDIMOHNIIME1011111111111111111111111111111111101111111111111111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201903283UA 2016-10-12 2017-10-12 Methods and compositions for tusc2 immunotherapy SG11201903283UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407329P 2016-10-12 2016-10-12
PCT/US2017/056338 WO2018071668A1 (en) 2016-10-12 2017-10-12 Methods and compositions for tusc2 immunotherapy

Publications (1)

Publication Number Publication Date
SG11201903283UA true SG11201903283UA (en) 2019-05-30

Family

ID=61906060

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903283UA SG11201903283UA (en) 2016-10-12 2017-10-12 Methods and compositions for tusc2 immunotherapy

Country Status (15)

Country Link
US (3) US11278592B2 (en)
EP (1) EP3525809A4 (en)
JP (3) JP7041136B2 (en)
KR (1) KR102661905B1 (en)
CN (2) CN116672456A (en)
AU (2) AU2017342364B2 (en)
BR (1) BR112019007365A2 (en)
CA (1) CA3040458A1 (en)
CL (1) CL2019001002A1 (en)
IL (2) IL322445A (en)
MA (1) MA46542A (en)
MX (1) MX386249B (en)
RU (1) RU2755903C2 (en)
SG (1) SG11201903283UA (en)
WO (1) WO2018071668A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3138555T (en) 2014-04-30 2021-03-25 Fujifilm Corporation LIPOSOME COMPOSITION AND MANUFACTURING METHOD
SG11201903283UA (en) * 2016-10-12 2019-05-30 Univ Texas Methods and compositions for tusc2 immunotherapy
WO2019244978A1 (en) 2018-06-20 2019-12-26 富士フイルム株式会社 Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
CN116121194B (en) * 2023-02-27 2023-10-24 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) A lung cancer immunotherapy-resistant cell line and its preparation method and application
CN116482368B (en) * 2023-05-09 2025-09-26 扬州大学 Preparation method of a biosensor for targeted detection of microRNA in tumor-derived extracellular vesicles
WO2025208148A1 (en) * 2024-03-29 2025-10-02 Genprex, Inc. Maintenance therapy for treating cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5397987A (en) 1993-03-03 1995-03-14 Rheometrics, Inc. Method and apparatus for analyzing samples using nuclear magnetic resonance
WO1995001994A1 (en) 1993-07-09 1995-01-19 Synergen, Inc. Recombinant ctla4 polypeptides and methods for making the same
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP0955999B1 (en) 1996-08-19 2001-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Novel liposome complexes for increased systemic delivery
EP0948343B1 (en) 1996-11-21 2006-02-08 Promega Corporation Alkyl peptide amides adapted for topical administration
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
ATE354655T1 (en) 1999-08-24 2007-03-15 Medarex Inc HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
JP4813746B2 (en) 2000-07-10 2011-11-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Chromosome 3p21.3 gene is a tumor suppressor
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
AU2002324723B2 (en) 2001-08-16 2007-10-25 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
AU2003279010A1 (en) 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
KR101325023B1 (en) 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Compositions and methods for regulating nk cell activity
CN104645327A (en) 2003-07-24 2015-05-27 依奈特制药公司 Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
PT1836225E (en) 2005-01-06 2012-01-10 Novo Nordisk As Kir-binding agents and methods of use thereof
JP2008532521A (en) 2005-03-09 2008-08-21 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Novel hTMC promoter and vector for tumor selective and highly efficient expression of cancer therapeutic genes
US8338366B2 (en) 2005-03-14 2012-12-25 The Board of Regents of the University of the Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
PL2161336T5 (en) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
MX2008013618A (en) 2006-05-09 2008-10-30 Colgate Palmolive Co Oral care regimen.
ES2579768T3 (en) 2007-01-11 2016-08-16 Novo Nordisk A/S Anti-KIR antibodies, formulations and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
CN102666581A (en) 2009-08-31 2012-09-12 艾普利穆恩公司 Methods and compositions for the inhibition of transplant rejection
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
JP5705242B2 (en) 2010-02-19 2015-04-22 ゼンコア インコーポレイテッド Novel CTLA4-IG immune adhesin
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EA035033B1 (en) 2010-11-22 2020-04-20 Иннейт Фарма Са Method for treatment of hematological pre-malignancy or hematological malignancy
CA2864394C (en) * 2011-03-02 2021-10-19 Jack Roth A method of predicting a response to a tusc2 therapy
CA2837184C (en) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
WO2013148158A1 (en) * 2012-03-30 2013-10-03 President And Fellows Of Harvard College Laser-actuated therapeutic nanoparticles
JP2014022858A (en) 2012-07-17 2014-02-03 Murata Mfg Co Ltd Power amplifier
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
JP6611709B2 (en) * 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド Use of a semaphorin-4D inhibitor molecule in combination with immunomodulatory therapy to inhibit tumor growth and metastasis
RU2016107426A (en) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. COMBINING CD27 AGONISTS AND INHIBITING IMMUNE CONTROL POINTS TO STIMULATE IMMUNITY
PT3702373T (en) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
JOP20200094A1 (en) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
US20170246298A1 (en) * 2014-09-24 2017-08-31 Apellis Pharmaceuticals, Inc. Methods and compositions for cancer treatment and treatment selection
SG11201903283UA (en) * 2016-10-12 2019-05-30 Univ Texas Methods and compositions for tusc2 immunotherapy

Also Published As

Publication number Publication date
AU2023201601A1 (en) 2023-04-13
EP3525809A1 (en) 2019-08-21
JP2024057000A (en) 2024-04-23
EP3525809A4 (en) 2020-06-03
AU2017342364A1 (en) 2019-05-23
US20260027180A1 (en) 2026-01-29
KR102661905B1 (en) 2024-04-29
IL265965B1 (en) 2026-01-01
CL2019001002A1 (en) 2019-11-08
CN110072540B (en) 2023-06-02
RU2019114031A (en) 2020-11-13
MX386249B (en) 2025-03-18
RU2755903C2 (en) 2021-09-22
RU2019114031A3 (en) 2020-11-13
JP2022081616A (en) 2022-05-31
CN116672456A (en) 2023-09-01
AU2017342364B2 (en) 2022-12-15
JP2019534268A (en) 2019-11-28
CA3040458A1 (en) 2018-04-19
US20200038480A1 (en) 2020-02-06
KR20190067216A (en) 2019-06-14
JP7041136B2 (en) 2022-03-23
MA46542A (en) 2021-03-31
IL265965A (en) 2019-06-30
US11278592B2 (en) 2022-03-22
CN110072540A (en) 2019-07-30
WO2018071668A1 (en) 2018-04-19
US12485159B2 (en) 2025-12-02
US20220168388A1 (en) 2022-06-02
AU2023201601B2 (en) 2026-02-05
BR112019007365A2 (en) 2019-07-09
IL322445A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
SG11201903283UA (en) Methods and compositions for tusc2 immunotherapy
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201901126UA (en) Combination therapy for cancer
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer